PL2150617T3 - Wzmocniona ekspresja i regiony stabilności - Google Patents

Wzmocniona ekspresja i regiony stabilności

Info

Publication number
PL2150617T3
PL2150617T3 PL08756678T PL08756678T PL2150617T3 PL 2150617 T3 PL2150617 T3 PL 2150617T3 PL 08756678 T PL08756678 T PL 08756678T PL 08756678 T PL08756678 T PL 08756678T PL 2150617 T3 PL2150617 T3 PL 2150617T3
Authority
PL
Poland
Prior art keywords
enhanced expression
stability regions
regions
stability
enhanced
Prior art date
Application number
PL08756678T
Other languages
English (en)
Inventor
Gang Chen
Robert Babb
James P Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39736874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2150617(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL2150617T3 publication Critical patent/PL2150617T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08756678T 2007-06-04 2008-06-04 Wzmocniona ekspresja i regiony stabilności PL2150617T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93321307P 2007-06-04 2007-06-04
EP08756678.2A EP2150617B1 (en) 2007-06-04 2008-06-04 Enhanced expression and stability regions
PCT/US2008/065733 WO2008151219A1 (en) 2007-06-04 2008-06-04 Enhanced expression and stability regions

Publications (1)

Publication Number Publication Date
PL2150617T3 true PL2150617T3 (pl) 2015-04-30

Family

ID=39736874

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08756678T PL2150617T3 (pl) 2007-06-04 2008-06-04 Wzmocniona ekspresja i regiony stabilności

Country Status (6)

Country Link
US (6) US7771997B2 (pl)
EP (1) EP2150617B1 (pl)
DK (1) DK2150617T3 (pl)
ES (1) ES2522615T3 (pl)
PL (1) PL2150617T3 (pl)
WO (1) WO2008151219A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
HUE038596T2 (hu) 2009-06-02 2018-10-29 Regeneron Pharma Fukoziláció-hiányos sejtek
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
US9910038B2 (en) 2012-11-30 2018-03-06 Larix Bioscience, Llc Cell line screening method
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
KR20150127596A (ko) 2013-03-14 2015-11-17 리제너론 파아마슈티컬스, 인크. 아펠린 융합 단백질 및 이들의 용도
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EA201991976A1 (ru) 2013-10-11 2020-04-02 Регенерон Фармасьютикалз, Инк. Метаболически оптимизированная клеточная культура
CN103642560A (zh) * 2013-10-14 2014-03-19 无锡通用钢绳有限公司 一种钢丝绳表面脂及其制备方法
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
MX2017005306A (es) * 2014-10-23 2018-01-09 Regeneron Pharma Novedosos sitios de integracion en celulas cho y usos de estos.
TW201702380A (zh) * 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
TWI735433B (zh) 2015-03-27 2021-08-11 美商再生元醫藥公司 偵測生物污染物之組成物及方法
PL3294775T3 (pl) 2015-05-12 2021-12-13 Regeneron Pharmaceuticals, Inc. Oznaczanie czystości białka multimerycznego
MX2017017117A (es) 2015-07-06 2018-03-06 Regeneron Pharma Moleculas multiespecificas de union a antigenos y usos de estas.
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CA3015389A1 (en) * 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
KR20180134894A (ko) 2016-04-20 2018-12-19 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
US20200317738A1 (en) 2016-05-26 2020-10-08 University College Cork - National University Of Ireland, Cork Methods for increasing proliferation of mammalian cells
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
PL3761035T3 (pl) 2016-08-18 2024-06-24 Regeneron Pharmaceuticals, Inc. Test do określania potencjału samoasocjacji białka za pomocą spektroskopii zależnych od stężenia samoodziaływań nanocząstek
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP2019534263A (ja) 2016-10-07 2019-11-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 室温で安定な凍結乾燥タンパク質
US11781116B2 (en) 2017-02-17 2023-10-10 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
CN111372946B (zh) 2017-02-17 2024-08-13 隆萨有限公司 难以表达的蛋白质的多位点特异性整合细胞
SG11201912548XA (en) 2017-07-06 2020-01-30 Regeneron Pharma Cell culture process for making a glycoprotein
US11833178B2 (en) 2017-08-25 2023-12-05 University College Cork—National University of Ireland, Cork Bifidobacterium longum for treating obesity and weight management
JP2020534813A (ja) 2017-09-08 2020-12-03 ライフ テクノロジーズ コーポレイション 改良された相同組換えおよびその組成物のための方法
EP3679143A1 (en) 2017-09-08 2020-07-15 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
US20200345051A1 (en) 2017-11-24 2020-11-05 University College Cork, National University Of Ireland, Cork A composition comprising a cohort of bacteria
JP7328990B2 (ja) 2018-04-30 2023-08-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
EP3604507A1 (en) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork An omega-transaminase enzyme
CA3134705A1 (en) 2019-04-02 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene
WO2021032650A1 (en) 2019-08-20 2021-02-25 Nuritas Limited Peptides for treating muscle atrophy
EP3783012A1 (en) 2019-08-20 2021-02-24 Nuritas Limited An antimicrobial peptide
JP2022553367A (ja) 2019-10-22 2022-12-22 ニューリタス リミテッド 非アルコール性脂肪肝の治療
EP4070670A1 (en) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 and uses thereof
AU2022259568A1 (en) 2021-04-14 2023-11-09 University College Cork - National University Of Ireland, Cork Psg1 for use in the treatment of osteoarthritis
JP2024514195A (ja) 2021-04-14 2024-03-28 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 脳血管イベントおよび神経障害の治療
CN118076894A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH建模和控制的系统及方法
EP4413359A1 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
IL312148A (en) 2021-10-18 2024-06-01 Regeneron Pharma Controlled transcription of polynucleotides
TW202323529A (zh) 2021-10-18 2023-06-16 美商再生元醫藥公司 包括腺病毒相關病毒聚核苷酸的真核細胞
CN118451189A (zh) 2021-10-18 2024-08-06 瑞泽恩制药公司 包括用于产生稳定整合位点的整合的cas9基因的哺乳动物细胞，以及包括稳定整合位点和其它位点的哺乳动物细胞
WO2024078729A1 (en) 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US6689606B2 (en) * 1998-07-21 2004-02-10 M.L. Laboratories Plc Polynucleotide
AU2002254529A1 (en) * 2001-04-04 2002-10-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Nucleic acids for transgene expression
FR2910490B1 (fr) 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions

Also Published As

Publication number Publication date
US9562238B2 (en) 2017-02-07
ES2522615T3 (es) 2014-11-17
US9932605B2 (en) 2018-04-03
US7771997B2 (en) 2010-08-10
US20160097059A1 (en) 2016-04-07
US9222106B2 (en) 2015-12-29
US20100291626A1 (en) 2010-11-18
DK2150617T3 (en) 2015-01-12
US20090124005A1 (en) 2009-05-14
US8389239B2 (en) 2013-03-05
US10415055B2 (en) 2019-09-17
WO2008151219A1 (en) 2008-12-11
US20170096681A1 (en) 2017-04-06
US20180327777A1 (en) 2018-11-15
US20130130372A1 (en) 2013-05-23
EP2150617B1 (en) 2014-10-22
EP2150617A1 (en) 2010-02-10

Similar Documents

Publication Publication Date Title
PL2150617T3 (pl) Wzmocniona ekspresja i regiony stabilności
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
EP2185692A4 (en) HCO32 AND HCO27 AND RELATED EXAMPLES
HK1196358A1 (en) Substituted pyridin-2-ones and pyridazin-3-ones -2--3-
IL210804A (en) Benzylidenehydrazides and their uses
EP2069496A4 (en) SELEX AND PHOTOSELEX ENHANCED
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
ZA200810323B (en) Fkbp-l and uses thereof
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
PT2114900T (pt) Compostos à base de tiopirimidina e as suas utilizações
LT2064327T (lt) Dbait ir jų panaudojimas
GB0808575D0 (en) Compilign and linking
GB0921531D0 (en) Playpen and related playpen set
GB0822154D0 (en) Recepatacle and support
ZA201103456B (en) Leukolectins and uses thereof
HK1133552A1 (en) Carboranylporphyrins and uses thereof
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
IL208771A0 (en) Iminopyridine derivatives and use thereof
PL2247601T3 (pl) Tiazopirymidynony i ich zastosowanie
EP2213675A4 (en) PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF
EP2133326A4 (en) NEW PSEUDOGLYCOLIPID AND ITS USE
ZA201001402B (en) Mouse and stay thereof
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
IL206951A0 (en) 3-alkyl-piperazine derivatives and uses thereof
EP2274294A4 (en) 5-DIMETHOXY FUMAGILLOL AND ITS DERIVATIVES